{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:01:55Z","timestamp":1784523715275,"version":"3.55.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-PSMA-617 has been shown to improve survival outcomes in patients with end-stage metastatic castration-resistant prostate cancer. However, data in earlier lines remain limited. In this study, we intended to evaluate the efficacy and safety of <jats:sup>177<\/jats:sup>Lu-PSMA-617 in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Hormone-sensitive prostate cancer patients with synchronous high-volume metastases (defined as \u22654 skeletal metastases with \u22651 extra-axial site or any visceral metastasis) showing high PSMA expression on <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT and ineligible\/unwilling for conventional chemohormonal treatment options were selected. Approximately, ~5.55\u20137.4 GBq of <jats:sup>177<\/jats:sup>Lu-PSMA-617 was administered intravenously at 8\u201312 weeks intervals, up to 6 cycles. All patients underwent concomitant androgen deprivation therapy\/orchiectomy. The outcome measures included the proportion of patients achieving an undetectable serum prostate-specific antigen (PSA) (ie, \u22640.2 ng\/mL) at any time point after therapy, best PSA response rate, objective radiographic response rate, radiographic progression-free survival, overall survival, and adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Ten patients with high-volume mHSPC received a median cumulative activity of 32.4 GBq (range, 7.4\u201344.4) of <jats:sup>177<\/jats:sup>Lu-PSMA-617 over 1\u20136 cycles. Five patients (50%) achieved an undetectable PSA with 9 patients (90%) showing a \u226550% decline in PSA from baseline. Nine patients underwent radiological follow-up, of which 7 (77.8%) had an objective response. The median radiographic progression-free survival was 24 months (95% confidence interval, 18\u201330), whereas the median overall survival was not reached. None of the patients had any grade 3\/4 adverse event.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-PSMA-617 seems to be a promising efficacious and safe treatment option for patients with synchronous high-volume mHSPC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005000","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T06:00:23Z","timestamp":1701756023000},"page":"131-137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Promising Therapeutic Activity of 177Lu-PSMA-617 in Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer"],"prefix":"10.1097","volume":"49","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Prasad","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","year":"2023","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","year":"2021","journal-title":"Eur Urol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40487-020-00119-z","article-title":"Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting","volume":"8","year":"2020","journal-title":"Oncol Ther"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaccao.2019.09.005","article-title":"The emerging and promising role of care for cardiometabolic syndrome in prostate cancer","volume":"1","year":"2019","journal-title":"JACC CardioOncol"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","year":"2019","journal-title":"AJR Am J Roentgenol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib15-20250621","first-page":"1726","article-title":"[177Lu]Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized, controlled trial","volume":"64","year":"2023"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","article-title":"Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study","volume":"27","year":"2021","journal-title":"Clin Cancer Res"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/cancers15010297","article-title":"PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study","volume":"15","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","article-title":"Short-course 177Lu-PSMA-617 radioligand therapy in high-volume metastatic hormone-sensitive prostate cancer: time to take the leap?","volume":"80","year":"2021","journal-title":"Eur Urol"},{"key":"bib19-20250621","first-page":"550","article-title":"Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the first global prostate cancer consensus conference for developing countries (PCCCDC)","volume":"7","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2967\/jnumed.123.265414","article-title":"[177Lu]Lu-PSMA-radioligand therapy efficacy outcomes in taxane-na\u00efve versus taxane-treated patients with metastatic castration-resistant prostate cancer: a systematic review and metaanalysis","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2967\/jnumed.121.261906","article-title":"Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality?","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials","volume":"28","year":"2023","journal-title":"Oncologist"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:03:07Z","timestamp":1750532587000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005000"}},"subtitle":["A Pilot Experience"],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005000","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}